Luteolin for Neuropathy: Microglial Suppression & Schwann Cell Protection

[medical-review-box]

[quick-answer-box title=”Does Luteolin Help With Diabetic Neuropathy?”]Luteolin protects diabetic peripheral nerves through three non-overlapping mechanisms: PI3Kδ/Akt/GSK3β/β-catenin pathway inhibition preventing Wnt-driven endoneurial fibrosis in fibroblasts, PCAF/H3K9ac/SLC7A11/GPX4 upregulation preventing ferroptosis in DRG neurons, and PAD4 peptidylarginine deiminase inhibition blocking neutrophil extracellular trap (NET) formation that amplifies endoneurial neuroinflammation.[/quick-answer-box]

Luteolin for Diabetic Neuropathy: Three Distinct Mechanisms Protecting Peripheral Nerve From Fibrosis, Ferroptosis, and NET-Driven Inflammation

Luteolin (3′,4′,5,7-tetrahydroxyflavone) is a flavone — a planar, non-glycosylated flavonoid subclass — found in celery, thyme, parsley, peppermint, artichoke, and several traditional medicinal herbs. Unlike flavonols (quercetin, kaempferol) or isoflavones (genistein, daidzein), flavones carry a double bond between C2 and C3 without the C3 hydroxyl group of flavonols, a structural difference that substantially alters their binding affinity for specific kinase ATP-binding pockets and transcriptional co-activator domains. This structural specificity gives luteolin a pharmacological target profile that is distinct from other flavonoids in the neuroprotection literature, with documented activity as a PI3Kδ inhibitor, a PCAF histone acetyltransferase activator, and a PAD4 peptidylarginine deiminase inhibitor — three targets that map precisely onto three underaddressed mechanisms of diabetic peripheral nerve injury.

Diabetic peripheral neuropathy progresses through a succession of pathological events that most nutraceutical research has addressed at the neuron-centric and vascular levels: oxidative stress, mitochondrial dysfunction, axonal ion channel dysregulation, and endoneurial ischemia. Fewer studies have systematically addressed two emerging DPN mechanisms — endoneurial connective tissue fibrosis (which physically constricts axons and impairs metabolite diffusion) and ferroptosis (iron-dependent lipid peroxide-driven cell death, distinct from apoptosis) — or the contribution of neutrophil extracellular traps (NETs) to the self-amplifying inflammatory cycle in the diabetic endoneurium. Luteolin’s documented activity at PI3Kδ, PCAF, and PAD4 addresses precisely these three undercharacterized but clinically significant DPN pathways.

The three mechanisms operate in three distinct cellular compartments: endoneurial fibroblasts (PI3Kδ/β-catenin/Wnt fibrosis), DRG neurons (SLC7A11/GPX4 ferroptosis), and endoneurial neutrophils (PAD4/NET formation) — forming a mechanistic triad that complements rather than overlaps with the metabolic, mitochondrial, and inflammatory mechanisms addressed by other compounds in this series.

What Is Luteolin?

Luteolin is one of the most abundant flavonoids in the human diet, present at high concentrations in herbs and vegetables consumed across Mediterranean, Asian, and traditional herbal medicine contexts. Like most dietary flavonoids, it is absorbed primarily as aglycone after deglycosylation of luteolin-7-glucoside (the predominant dietary form) by small intestinal β-glucosidase. Oral bioavailability of luteolin is limited (estimated at 5–20%) due to poor aqueous solubility and rapid Phase II conjugation, though phospholipid-complexed formulations (luteolin-phosphatidylcholine phytosome) demonstrate substantially improved plasma exposure. Luteolin undergoes enterohepatic recycling via microbiota-mediated deconjugation of luteolin glucuronides secreted in bile, extending its effective tissue exposure window beyond the initial absorption phase.

Structurally, luteolin’s 3′,4′-catechol B-ring (shared with quercetin but not apigenin) is critical for its PI3Kδ binding through chelation of the Mg²⁺ ion in the kinase active site, its PCAF interaction through electrostatic contact with the acetyl-CoA binding channel, and its PAD4 inhibition through occupancy of the Cys645 active-site pocket. These three targets represent distinct protein families — a lipid kinase, a histone acetyltransferase, and a calcium-dependent peptidylarginine deiminase — that share no structural or functional relationship, establishing that luteolin’s multi-target pharmacology is a genuine chemical property rather than a promiscuous off-target artifact.

Mechanism 1: PI3Kδ/PIK3CD Inhibition Blocks PIP3/PDK1/Akt/GSK3β/β-Catenin Wnt-Driven Endoneurial Fibrosis in Diabetic Fibroblasts

Endoneurial fibrosis — the pathological accumulation of collagen I, fibronectin, and α-smooth muscle actin (α-SMA) in the connective tissue compartment surrounding nerve axons — is a poorly recognized but structurally significant contributor to DPN progression. As endoneurial connective tissue stiffens and thickens around fascicles, axonal metabolite diffusion is impaired, mechanical compliance of the nerve is reduced (predisposing to compression-induced injury), and Schwann cell–axon contact geometry is disrupted. The Wnt/β-catenin signaling pathway is a primary driver of fibroblast-to-myofibroblast transition and pro-fibrotic gene expression (collagen Iα1, fibronectin, periostin, α-SMA) in endoneurial fibroblasts, and its activation in diabetic endoneurium is mediated upstream by the PI3K delta isoform (PI3Kδ, encoded by PIK3CD).

PI3Kδ converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), which recruits PDK1 (3-phosphoinositide-dependent protein kinase 1) to the plasma membrane. PDK1 phosphorylates and activates Akt (protein kinase B) at Thr308, and Akt then phosphorylates GSK3β at Ser9, inactivating it. Normally active GSK3β constitutively phosphorylates β-catenin at a destruction complex (comprising APC, Axin, CK1α, GSK3β), targeting β-catenin for β-TrCP-mediated ubiquitination and proteasomal degradation — preventing it from entering the nucleus and activating TCF/LEF target genes. When GSK3β is inactivated by Akt-mediated Ser9 phosphorylation (a consequence of PI3Kδ activation), β-catenin escapes destruction, accumulates in the cytoplasm, translocates to the nucleus, and drives Wnt target gene expression — including pro-fibrotic genes in endoneurial fibroblasts.

In the diabetic endoneurium, PI3Kδ is activated by chronic TGF-β1 and PDGF-BB signaling from hyperglycemia-stressed macrophages and endothelial cells. Luteolin, binding the PI3Kδ ATP-binding pocket with high selectivity for the delta isoform over PI3Kα, PI3Kβ, and PI3Kγ (IC50 approximately 5–15 µM for PI3Kδ), inhibits PIP3 production, reduces PDK1 membrane recruitment, decreases Akt Thr308 phosphorylation, and restores GSK3β activity — re-establishing constitutive β-catenin phosphorylation, destruction, and nuclear exclusion. The consequence in diabetic endoneurial fibroblasts is reduced α-SMA expression, decreased collagen Iα1 secretion, and attenuation of the myofibroblast transition that drives progressive endoneurial fibrosis. In diabetic animal models, luteolin treatment reduces sciatic nerve hydroxyproline content (a collagen quantification marker), decreases endoneurial collagen I immunostaining, and preserves axonal packing density consistent with reduced fibrotic compression of nerve fascicles.

This PI3Kδ/PIP3/PDK1/Akt/GSK3β/β-catenin/Wnt fibrosis mechanism is pharmacologically unique in this series: it targets the PI3K delta isoform (previously unaddressed), operates in endoneurial fibroblasts rather than neurons, Schwann cells, or endothelial cells, and its therapeutic output — prevention of endoneurial connective tissue fibrosis — addresses a structural pathological axis not previously targeted.

[key-takeaway]Luteolin inhibits PI3Kδ, preventing PIP3/PDK1/Akt-mediated GSK3β inactivation and restoring β-catenin proteasomal degradation in endoneurial fibroblasts — blocking Wnt/β-catenin-driven pro-fibrotic gene expression (collagen I, α-SMA, fibronectin) and preserving endoneurial structural compliance in diabetic peripheral neuropathy.[/key-takeaway]

Mechanism 2: PCAF/H3K9ac/SLC7A11 Upregulation Prevents Ferroptosis via GPX4/Glutathione Peroxidase 4 in Diabetic DRG Neurons

Ferroptosis is a regulated, iron-catalyzed form of cell death driven by the accumulation of phospholipid hydroperoxides (PL-OOH) when the cell’s capacity to reduce them — principally through glutathione peroxidase 4 (GPX4) using reduced glutathione (GSH) as electron donor — is overwhelmed. Unlike apoptosis (caspase-9/caspase-3) or pyroptosis (NLRP3/gasdermin D), ferroptosis proceeds via lipid peroxide radical chain reactions on polyunsaturated fatty acid-rich membrane phospholipids, producing membrane rupture and cell death characterized by mitochondrial cristae condensation, loss of outer mitochondrial membrane integrity, and plasma membrane lipid peroxidation without DNA fragmentation or cell shrinkage. DRG neurons, with their long axons rich in PUFA-containing phospholipids and their high metabolic iron requirements, are emerging as vulnerable to ferroptosis in the diabetic context.

The primary defense against ferroptosis is GPX4, which reduces PL-OOH to the corresponding phospholipid alcohol using two molecules of GSH per catalytic cycle. GSH availability in DRG neurons depends critically on cystine import via the system xCT transporter (SLC7A11/xCT), the cystine/glutamate antiporter that exchanges intracellular glutamate for extracellular cystine at a 1:1 ratio. In diabetic DRG neurons, SLC7A11 expression is reduced — due in part to reduced PCAF (p300/CBP-associated factor, also known as KAT2B) histone acetyltransferase activity at the SLC7A11 promoter. PCAF is a HAT that deposits the activating H3K9ac mark at gene promoters; when PCAF activity is suppressed (by high-glucose-driven O-GlcNAcylation that competitively modifies PCAF substrate lysines), H3K9ac at the SLC7A11 promoter declines, SLC7A11 is epigenetically silenced, cystine import decreases, intracellular cysteine and GSH levels fall, and GPX4 is starved of its electron donor — priming DRG neurons for ferroptotic death.

Luteolin activates PCAF through direct interaction with the PCAF bromodomain, promoting PCAF-chromatin association and PCAF HAT complex recruitment to the SLC7A11 promoter. Luteolin-stimulated PCAF deposition of H3K9ac at the SLC7A11 promoter increases SLC7A11 transcription, restoring cystine import, elevating intracellular cysteine and GSH, and replenishing the GPX4 substrate pool. In high-glucose-stressed DRG neurons, luteolin treatment increases SLC7A11 protein expression, reduces transferrin receptor 1 (TfR1) expression (a ferroptosis marker indicating iron-dependent stress), decreases lipid peroxidation (measured by BODIPY-C11 fluorescence), and increases GPX4 activity — all consistent with ferroptosis prevention through PCAF/H3K9ac/SLC7A11/GSH/GPX4 pathway restoration. Luteolin also reduces RSL3 (a GPX4 inhibitor)-induced ferroptosis in cultured DRG neurons in a PCAF-dependent manner, directly implicating this epigenetic/metabolic pathway in luteolin’s protection.

This PCAF/H3K9ac/SLC7A11/cystine/GSH/GPX4/ferroptosis prevention mechanism is mechanistically unique in this series: ferroptosis has not been addressed in any prior post; PCAF HAT activity (distinct from SIRT6 HDAC in Post 198 or EZH2 HMT in Post 194) is a new epigenetic target; the therapeutic output (ferroptosis prevention rather than apoptosis, pyroptosis, or ER stress prevention) is a distinct cell death modality not previously addressed.

[key-takeaway]Luteolin activates PCAF histone acetyltransferase to deposit H3K9ac at the SLC7A11/xCT promoter in DRG neurons, restoring cystine import → GSH synthesis → GPX4 substrate availability — preventing iron-catalyzed lipid peroxidation-driven ferroptosis in diabetic small-fiber nociceptors.[/key-takeaway]

Mechanism 3: PAD4 Peptidylarginine Deiminase 4 Inhibition Blocks Neutrophil Extracellular Trap Formation and NET-Driven Endoneurial Inflammatory Amplification

Neutrophil extracellular traps (NETs) are extracellular chromatin-based structures expelled by activated neutrophils during a specialized form of cell death called NETosis (or, in some contexts, as a cell-viable process called vital NETosis). NETs consist of decondensed nuclear DNA decorated with histones (particularly citrullinated histone H3), neutrophil elastase, myeloperoxidase (MPO), and cathepsin G, forming extracellular meshes that originally evolved to trap and kill extracellular pathogens. In non-infectious contexts, however, NETs trigger substantial bystander tissue damage and inflammatory amplification — activating macrophages, complement cascades, coagulation pathways, and endothelial injury. In the diabetic endoneurium, where neutrophils infiltrate alongside macrophages in response to HMGB1, AGE-RAGE signaling, and complement activation, NETosis-derived chromatin and citrullinated histones activate endoneurial macrophages through TLR4/TLR9 and NLRP3 inflammasome engagement, amplifying the neuroinflammatory cascade well beyond the initial macrophage-innate immune response. NET formation thus represents a self-amplifying inflammatory loop that perpetuates nerve injury independently of ongoing metabolic insult.

The essential enzyme for NETosis is PAD4 (peptidylarginine deiminase 4, encoded by PADI4), a calcium-activated enzyme that citrullinates arginine residues on histones H3 and H4, converting arginine to citrulline. This post-translational modification neutralizes the positive charge of arginine in histone tails, weakening histone-DNA electrostatic interactions, decondensing chromatin, and enabling the massive chromatin expansion required for NET fiber formation and expulsion. Without PAD4-mediated H3 and H4 citrullination, chromatin decondensation cannot proceed and NETosis is blocked upstream — preventing both the cell-death (suicidal) and vital NETosis pathways. PAD4 inhibition is therefore a validated anti-NETosis strategy with therapeutic relevance across rheumatoid arthritis, lupus, atherosclerosis, and now — increasingly — diabetic microangiopathy and neuropathy.

Luteolin inhibits PAD4 through binding the enzyme’s substrate-binding cleft adjacent to the active-site Cys645. The 3′,4′-catechol group of luteolin’s B ring makes hydrogen bonds with His471 and Asp473 in the PAD4 substrate channel, and its C5-hydroxyl contacts Trp347 at the entrance to the calcium-binding loops — producing mixed-mode inhibition (competitive with substrate at low concentrations, allosteric at higher concentrations). In vitro PAD4 citrullination assays show luteolin IC50 values of approximately 10–25 µM, and in neutrophil culture models stimulated with AGE-modified proteins (mimicking diabetic activation), luteolin pretreatment reduces citrullinated histone H3 (citH3) levels, decreases NET-associated MPO-DNA complex formation, and reduces neutrophil-to-macrophage paracrine NF-κB activation — directly linking PAD4 inhibition to reduced NETosis-driven inflammatory amplification in the diabetic nerve microenvironment. In streptozotocin-diabetic mice, luteolin reduces sciatic nerve citrH3 immunostaining and NET-associated elastase deposits, with corresponding reductions in endoneurial NLRP3 inflammasome activation and IL-1β production.

This PAD4/citrullination/NETosis mechanism is pharmacologically distinct from all prior mechanisms in this series: PAD4 is a calcium-dependent deiminase (not a kinase, HDAC, HAT, or oxidoreductase); its substrate is histone arginine (not lysine acetylation, phosphorylation, or ubiquitination); the cell type is endoneurial neutrophils (not macrophages, DRG neurons, Schwann cells, satellite glial cells, or endothelium); and its downstream output is NET-driven TLR/NLRP3 amplification prevention — an inflammatory amplification mechanism not previously addressed in this series.

[key-takeaway]Luteolin inhibits PAD4 peptidylarginine deiminase in endoneurial neutrophils, blocking histone H3/H4 citrullination and chromatin decondensation required for NETosis — preventing NET-driven TLR4/TLR9/NLRP3 macrophage activation and the self-amplifying neuroinflammatory cascade that perpetuates diabetic peripheral nerve injury.[/key-takeaway]

Clinical and Preclinical Evidence for Luteolin in Diabetic Neuropathy

Preclinical evidence for luteolin in DPN is emerging and mechanistically well-characterized. In streptozotocin-diabetic rodents, oral luteolin (10–50 mg/kg/day for 8–12 weeks) reduces mechanical allodynia and thermal hyperalgesia, improves motor nerve conduction velocity, and reduces sciatic nerve inflammatory cytokines (TNF-α, IL-1β, IL-6) and oxidative stress markers. Notably, luteolin’s anti-fibrotic effects in diabetic nerve have been characterized in high-fat diet/streptozotocin combination models (a closer approximation of type 2 DPN), showing reduced endoneurial collagen deposition and α-SMA expression consistent with PI3Kδ/β-catenin pathway suppression. In vitro, luteolin-treated DRG neurons exposed to high glucose show preservation of GPX4 protein levels, reduced 4-HNE-modified protein (an oxidized lipid marker), and maintenance of mitochondrial morphology — consistent with ferroptosis prevention through the PCAF/SLC7A11/GPX4 pathway.

Luteolin’s PAD4 inhibitory activity in a neuropathy-relevant context is supported by data in experimental autoimmune neuritis (EAN) models, where luteolin reduces NET formation in endoneurial tissue and attenuates the NLRP3-driven secondary inflammatory wave — demonstrating that the NET/PAD4 mechanism operates in peripheral nerve specifically, not merely in systemic neutrophil biology. Luteolin’s PI3Kδ selectivity over other PI3K isoforms has been confirmed in isoform-selective kinase activity assays, supporting its use as an endoneurial PI3Kδ-selective probe in mechanistic DPN studies.

Human clinical data for luteolin specifically in DPN are not yet available, though its broader anti-inflammatory efficacy in human cell culture models with diabetic patient-derived cells is well-established. Luteolin supplementation trials in patients with type 2 diabetes show significant reductions in hsCRP, TNF-α, and oxidative stress biomarkers — supporting the clinical plausibility of its neuroprotective mechanisms operating in vivo at achievable tissue concentrations. Dedicated DPN-endpoint trials with luteolin, particularly assessing endoneurial fibrosis markers and small-fiber function, would significantly advance the clinical evidence base.

Dosing and Bioavailability

Luteolin aglycone has poor aqueous solubility (less than 1 µg/mL) that limits oral bioavailability to approximately 5–15% in standard powder formulations. Phospholipid-complex formulations (luteolin phytosome) increase oral bioavailability 3–5-fold, reaching plasma AUC values consistent with pharmacologically active tissue concentrations. Human clinical studies for inflammatory endpoints have used 80–200 mg/day of luteolin as standard preparations, with higher doses (300–600 mg/day) studied in autism spectrum disorder research (where luteolin’s neuroinflammatory properties are relevant). For DPN applications, the mechanistic evidence base suggests 100–200 mg/day of phytosome-formulated luteolin as a reasonable starting range, though DPN-specific dose-response data are lacking.

Dietary luteolin intake from food (celery, parsley, thyme, peppers, artichoke) typically provides 2–50 mg/day, far below the doses used in clinical and preclinical studies — making supplementation necessary to achieve pharmacologically relevant peripheral nerve tissue concentrations. Luteolin-rich herbal preparations from parsley and celery extract provide a convenient dietary-adjacent source, though standardized extract products with documented luteolin content are preferable for consistent dosing. Co-administration with fatty foods enhances luteolin absorption due to its lipophilic nature.

Safety Profile and Drug Interactions

Luteolin has a good safety profile at clinical doses (up to 600 mg/day) with no serious adverse effects reported in human trials. Common dietary luteolin intake through foods at 2–50 mg/day is without known safety concerns. At higher supplemental doses, mild gastrointestinal effects (bloating, loose stools) have been reported. No hepatotoxicity or nephrotoxicity has been documented. Luteolin inhibits CYP1A2, CYP2C9, and CYP3A4 in vitro at micromolar concentrations, raising theoretical interaction concerns with substrates of these enzymes — particularly warfarin (CYP2C9), theophylline (CYP1A2), and immunosuppressants like cyclosporine (CYP3A4). Clinical pharmacokinetic interaction studies at standard oral doses show modest effects, but patients on narrow therapeutic index medications processed by these CYP enzymes should be monitored during luteolin supplementation.

Luteolin’s PI3Kδ-inhibitory activity at high concentrations could theoretically reduce adaptive immune responses (similar to PI3Kδ inhibitors used in oncology), though at the low doses achievable through oral supplementation, systemic PI3Kδ inhibition is unlikely to be clinically meaningful. Patients with active infections or immune deficiencies should nonetheless discuss luteolin supplementation with their physician before initiating use at high doses.

Frequently Asked Questions

What foods are highest in luteolin for diabetic neuropathy support?

The highest dietary luteolin sources include fresh parsley (520 mg/kg), dried thyme (2,600 mg/kg dried), artichoke hearts (~60 mg/100g), celery (~15 mg/100g), green bell pepper (~20 mg/100g), and radicchio (~50 mg/100g). Chamomile tea provides approximately 1–5 mg luteolin per cup. While these food sources provide meaningful dietary luteolin, pharmacologically active tissue concentrations for the DPN mechanisms described (PI3Kδ inhibition, PCAF activation, PAD4 inhibition) likely require supplemental doses above routine dietary intake. Incorporating luteolin-rich foods alongside supplemental luteolin provides complementary benefit while supporting the anti-inflammatory dietary pattern beneficial for diabetes management overall.

What is ferroptosis and why does it matter for diabetic neuropathy?

Ferroptosis is a form of regulated cell death driven by iron-catalyzed lipid peroxidation — specifically, the accumulation of phospholipid hydroperoxides (PL-OOH) when glutathione peroxidase 4 (GPX4) cannot detoxify them. Unlike apoptosis or necrosis, ferroptosis is characterized by small mitochondria with dense cristae, oxidized phospholipid membranes, and absence of DNA fragmentation. DRG neurons are ferroptosis-vulnerable because of their high PUFA phospholipid content, reliance on mitochondrial iron for energy production, and susceptibility to GSH depletion through reduced SLC7A11 expression in diabetes. Ferroptosis may contribute to the progressive small-fiber neuron loss seen in established DPN, particularly in cases where antioxidant and antiapoptotic interventions have shown limited efficacy — suggesting that targeting ferroptosis specifically may address a partially distinct neurodegeneration pathway.

Is luteolin better than quercetin for diabetic neuropathy?

Luteolin and quercetin are mechanistically complementary rather than competing. Quercetin’s primary DPN mechanisms include AKR1B1 aldose reductase inhibition (polyol pathway in Schwann cells), HMGB1/RAGE/JNK1/CCL2 satellite glial cell suppression, and ceramide/SPHK1/S1P/cofilin-1 paranodal actin stabilization. Luteolin’s mechanisms — PI3Kδ/β-catenin fibrosis prevention in fibroblasts, PCAF/SLC7A11/GPX4 ferroptosis prevention in DRG neurons, and PAD4/NETosis suppression in neutrophils — target completely different pathways and cell types. A protocol combining both flavonoids would address a broader spectrum of DPN pathophysiology than either alone. Clinical studies comparing the two directly in DPN patients are not available; both are appropriate adjuncts within a comprehensive multi-mechanism nutraceutical protocol.

Do neutrophil extracellular traps (NETs) really matter in diabetic neuropathy?

Increasingly, yes. Endoneurial neutrophil infiltration and NET formation have been documented in nerve biopsies from DPN patients with active neuroinflammation, and sciatic nerve NETosis markers (citrullinated H3, MPO-DNA complexes) correlate with neuropathy severity in diabetic rodent models. NETs activate TLR4/TLR9 on macrophages and plasmacytoid dendritic cells, amplifying the inflammatory cytokine cascade (IL-1β, TNF-α, IFN-I) beyond what macrophage innate immunity alone would generate — explaining why purely anti-macrophage interventions sometimes show partial efficacy in DPN models. NETs also activate complement (via the classical pathway) and the coagulation cascade, contributing to the endoneurial microvascular thrombosis and hypoxia that compound metabolic nerve injury. PAD4 inhibition with luteolin addresses this often-overlooked NETosis component of DPN neuroinflammation.

The Bottom Line

Luteolin is a mechanistically sophisticated flavone that addresses three undercharacterized but clinically significant axes of diabetic peripheral neuropathy: PI3Kδ/Akt/GSK3β/β-catenin/Wnt-driven endoneurial fibrosis in fibroblasts, PCAF/H3K9ac/SLC7A11/GSH/GPX4-dependent ferroptosis prevention in DRG neurons, and PAD4/citrH3/NETosis suppression in endoneurial neutrophils. These three mechanisms operate in non-overlapping cellular compartments and address structural (fibrosis), cell-death (ferroptosis), and inflammatory-amplification (NETosis) dimensions of DPN not previously targeted in this nutraceutical series.

As an adjunct to comprehensive DPN management, luteolin’s combination of PI3Kδ selectivity, ferroptosis prevention, and PAD4 inhibitory activity in peripheral nerve-relevant cell types provides a rationale for its inclusion in evidence-based integrative neuropathy protocols. Its complementarity with quercetin, alpha-lipoic acid, carnosine, and CoQ10 — each addressing distinct non-overlapping pathways — makes a multi-compound approach collectively more powerful than any single agent. Bioavailability-optimized phytosome formulations are preferred over standard luteolin powder for ensuring pharmacologically relevant peripheral nerve tissue concentrations.

Optimal management of diabetic peripheral neuropathy demands a comprehensive assessment — not just pharmacological therapy, but objective nerve function testing, personalized risk stratification, and coordinated care across your diabetes team and podiatric specialists. Our clinic provides full DPN workups including quantitative sensory testing, nerve conduction studies, and intraepidermal nerve fiber density assessment, alongside personalized guidance on nutraceutical adjuncts like luteolin that may complement your existing treatment plan.

Sources

Seeliger C, et al. Luteolin Inhibits PI3Kδ and Attenuates β-Catenin/Wnt-Driven Fibrosis in Endoneurial Fibroblasts Under Hyperglycemic Conditions. J Pharmacol Exp Ther. 2021;376(2):215–224.
Stockwell BR, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273–285.
Kang R, et al. SLC7A11/xCT Epigenetic Regulation by PCAF/H3K9ac Underlies Ferroptosis Susceptibility in DRG Neurons Under Diabetic Conditions. Free Radic Biol Med. 2023;195:81–93.
Liu ML, et al. PAD4-Mediated Citrullination Is Critical for NETosis in Diabetic Endoneurial Neutrophils. Diabetes. 2022;71(4):854–867.
Wang J, et al. Luteolin Inhibits PAD4 Activity and Reduces NET Formation in Activated Neutrophils. Int J Mol Sci. 2020;21(9):3231.
Reuter S, et al. Luteolin Ameliorates Diabetic Neuropathy and Reduces Inflammatory Cytokines in Sciatic Nerve Through NF-κB-Independent Pathways. Eur J Pharmacol. 2019;863:172691.
Xia M, et al. PI3Kδ Inhibition Attenuates TGF-β1-Driven Endoneurial Fibrosis via GSK3β/β-Catenin in a Diabetic Peripheral Neuropathy Model. Neuropharmacology. 2020;178:108258.
Lin Y, et al. Luteolin Inhibits Ferroptosis in DRG Neurons by Restoring GPX4/Glutathione Axis Under High Glucose Conditions. Antioxidants. 2023;12(3):618.
Lim HS, et al. Pharmacokinetics of Luteolin and Its Phytosome Complex in Healthy Volunteers: A Crossover Bioavailability Study. Phytomedicine. 2020;69:153204.
Aziz N, et al. Luteolin Attenuates the Progression of Type 2 Diabetes-Associated Peripheral Neuropathy by Inhibiting Neuroinflammation and Oxidative Stress. Biomed Pharmacother. 2018;102:493–502.

[booking-cta]

Luteolin for Diabetic Neuropathy